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Abstract 
Infratentorial cavernous malformations 
are still a source of serious controversies in 
neurosurgery and their natural history and 
treatment are intensely debated in 
literature. Recent studies suggest that 
symptomatic infratentorial cavernous 
malformations have a more aggressive 
clinical outcome than the supratentorial 
ones (the risk of hemorrhage is 
approximately 30 times that of the 
supratentorial cavernomas) The optimal 
therapeutic approach of infratentorial 
cavernomas need a good understanding of 
the natural history and also the 
characteristics that may influence the 
associated neurological risk, like the patient 
status at admission, the localization and the 
genetics of the malformation. Many studies 
have been published in the last decades to 
enlight the clinical aspects and the natural 
history of these vascular malformations. 
The purpose of this analysis is to make a 
literature review of the morbidity risk 
associated to cavernous malformations and 
their influence on the treatment plan.  
Keywords: natural history, infratentorial 
cavernomas, risk of hemorrhage 
Introduction 
Even if the first account of cavernoma 
surgery dates back to 1928 when Dandy 
evacuated a brain stem hemorrhage, 
resulted from a ruptured cavernoma studies 
on the natural history and management of 
these lesions appeared after 1980.  
Cavernous malformations are composed 
of a compact mass of sinusoidal-type vessels 
immediately in apposition to each other 
without any recognizable intervening 
neural parenchyma, delimited only by a 
row of endothelial of cells surrounded by 
conjunctive tissue. They may reach a 
considerable size and usually are round or 
lobulated. They can be classified on various 
criteria: number, location, type of 
development, MRI aspect, etc. The most 
used classification is: sporadic form, with 
unique lesions and familial form 
characterized by multiple lesions and a 
family history. 
The familial type of disease is found in 
20-30% of the patients with cavernous 
malformations. According to the time of 
appearance cavernomas can be congenital, 
present at birth (all cavernomas were 
considered congenital till 1990) and de 
novo, developed after birth, spontaneous or 
postiradiation.  
According to localization infratentorial 
cavernomas are classified in cerebellar 
(Figure 2) and brainstem cavernomas 
(Figure 1), this classification being 
extremely important in the therapeutic 
planning.  
 
 
 
 
Romanian Neurosurgery (2011) XVIII 4: 378 - 389          379 
 
 
 
 
A 
 
B 
 
C 
 
D 
 
E 
Figure 1 Pontin cavernoma, unverified operator in a 
patient found incidentally 35 years after a car 
accident: A, B – CT scan; C ,D, E -  MRI T2 axial 
section, T1 sagittal and T1 coronary section in the 
same patient with  pontin cavernoma (PDS). 
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Figure 2 Left cerebellar cavernoma (P.C., men, 18 
years old): A, B – CT scan; C, D, E - MRI T2 axial 
section, T1 coronary and T1 sagittal section. 
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Brainstem cavernomas are considered a 
special pathology given the risk of 
hemorrhage that is 30 times that of 
cavernomas elsewhere located, and the 
neurological deficits associated to 
hemorrhage. 
Intraventricular cavernomas (Figure 3) 
was reported in literature to account for 2,5 
to 10,8% of brain cavernomas. 
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Figure 3 IV ventricle cavernoma operated (63 years 
old, sex M): A, B – CT scan; C, D, E, F – brain MRI 
(N+K); G, H – postoperative CT scan 
Even small changes in brainstem 
cavernomas silent on MRI can cause major 
neurological deficits (23, 39). In the natural 
history of brainstem cavernomas 
contradicting characteristics have been 
reported. Some studies reported a benign 
tumor behavior (24), with a bleeding rate of 
2.46% per year and a rebleeding rate of 
5,1% per year, while other studies (40) 
reported a malignant natural history with a 
rate of rebleeding of 5% per year, and a 
rebleeding rate of  30%. The correct clinical 
evaluation and treatment of infratentorial 
cavernomas is based on hemorrhagic and 
neurological associated risk understanding, 
and also the factors that influence this risk. 
This study is aimed to review the 
knowledge on the natural history of 
infratentorial cavernomas and to make it 
ready usable for the neurosurgeon in 
treating these patients. 
Methods 
The literature data was selected and 
sorted from PubMed, using the keywords 
“natural history”, “cavernous 
malformation”, “cavernoma”, “cavernous 
angioma”, “cavernous hemangioma”, 
“hemorrhagic risk”, “neurologic risk”. This 
review was limited to studies published in 
english. The studies that provided 
information regarding the clinical 
presentation, risk of hemorrhage and 
prognostic factors (age, sex, dimension, and 
genetics) were investigated.  
Epidemiology 
There is no reliable study to offer precise 
information about the incidence and the 
prevalence of cavernomas. Based on 
cadaveric studies and IRM images, the 
prevalence was estimated 0,5% - 0,7% (15, 
43). The incidence of cavernomas was 
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estimated to 0,4% and 0,9%, accounting for  
8% - 15% of all intracranial vascular 
malformations. (15, 22, 32, 39). There is no 
gender difference even if some studies 
showed a small difference in favor of 
women (1, 23, 35, 40, 44, 48, 49). Up to 
25% of cavernomas appear in pediatric 
population. More than 60% are superficial, 
30% are profound (brainstem, cerebellar 
nuclei basal ganglia and thalamus) and 3% 
are located in spinal medulla. Multiple 
cavernomas appear in 90% of familial forms 
and in approx. 25% of sporadic forms (12, 
26). In average, 20% of cavernomas appear 
in posterior cranian fossa and 80% are 
supratentorial. The frequency of brainstem 
cavernoma is reported to be somewhere 
between 9% - 35% (24, 40). The average 
size of cavernomas is between 15 - 19 mm 
(22, 43). Only 10% of lesions remain 
unmodified in time; 35% grow and 55% 
shrink (12). This dynamic is related to 
recurrent bleeding and resorbtion of blood 
products or to changes in osmotic pressure 
(52). More and more authors agree to the 
presence of a subgroup of de novo 
cavernomas. (36). 
They can be frequently associated with 
venous angiomas (Figure 4), this 
relationship is more frequent in 
infratentorial types (18, 40). The large 
percent of associated lesions determined 
some authors to consider that the venous 
anomaly determines the cavernoma 
formation. (the affected venous drainage 
can take to capillary channels dilation). This 
theory is sustained by a rare observation: 
the cavernoma reccurency post resection 
was not reached in patients with associated 
DVA. (51). 
 
 
A 
 
B 
 
C 
 
 
 
384          M. Gorgan et al          Natural history of infratentorial cavernous malformations 
 
 
 
 
D 
 
E 
 
F 
Figure 4 Appearance MRI on three years after total 
resection of a cavernoma of the vermis and 
highlighting the marked increase in size of the three 
right cerebellar hemisphere cavernomas, placed 
around the venous angioma. Cavernomas was 
resected surgical and the angioma was treated 
conservatively: A – T1 axial section, B, C, D, E, - T2 
gradient echo axial section. 
Pathophysiology 
Cavernomas pathophysiology stands in a 
slow degradation of blood in cerebral 
parenchyma resulting in a hemosiderin 
ring, and perilezional gliosis. Almost all 
cavernous malformations have signs of 
recent hemorrhage. In contrast with a 
spontaneous intracerebral hemorrhage 
associated with hypertension, little is 
known about the physiopathology of 
cavernoma bleeding. 
Most of the microhemorrhages appear 
intralezional and this is the cavernomas 
growth mechanism, usually this 
microhemorrhage is asymptomatic. The 
situation of extralezional bleeding from a 
cavernoma is rare, it is cause for a 
intraparenchimal hematoma, usually being 
nonfatal, given the diminished blood flow 
and pressure inside the cavernoma. (46). 
Infratentorial cavernomas have a bleeding 
rate bigger than the supratentorial ones but 
the cause. Mechanisms of cavernomas 
volume growth (11): 
•Acute massive hemorrhage with 
sudden volume growth and mass effect or 
repeated small bleedings and thrombosis 
taking to a growing cystic lesion (41); 
•Chronic hemorrhage from thin walled 
vessels, with repeated reendotelisation, of 
the bleeding cavity, angiogenesis inside the 
developed hematoma, and perilezional 
matrix growth (30, 45); 
•Intraluminal thrombosis with 
recanalization and organization (42); 
•Angiogenesis proliferation with new 
capillaries as a phenomenon of reactive 
angiogenesis and consecutive 
neovascularization by coalescence (30); 
•Hemorrhage by adjacent cerebral 
parenchymal vessels erosion (33); 
•Imunohistochemical demonstrated 
proliferation (37,47); 
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•Nidus growth by new caverns 
formation (17, 27); 
•Vascular smooth muscle proliferation 
(3); 
Presentation 
Patients with cavernomas have a rich 
symptomatology with onset between 30 - 
50 years old. Bleeding inside the cavernoma 
and the compressive effect according to 
localization and dimensions are the 
mechanisms of clinical signs. The 
hemorrhage determines neurologic deficits 
depending on the location of the lesion, for 
example a bleeding from a brainstem 
cavernoma can result in cranial nerve 
deficits, like diplopia, facial palsy, vertigo, 
ophtalmoplegia, tinnitus, hearing loss, 
dysarthria and dysphagia.  Brainstem 
syndromes even as a consequence of 
ischemic lesions can be elicited also by 
cavernomas, according to their localization:  
Wallenberg syndrome, Millard-Gubler 
syndrome, Weber syndrome, Benedikt 
syndrome or Parinaud syndrome. 
Cerebellar hemorrhages in cerebral 
peduncles or on cerebellar can result in 
ataxia or nistagmus, but also cerebellar 
mutism was described. Cerebellar 
hemorrhage can also result in IV’th 
ventricle obstruction and hydrocephalus. 
Important hemorrhage in brainstem or 
pons cause loss of consciousness, coma and 
eventually death. The pons is a well-known 
site of fatal intracranian hemorrhage. All 
these neurological deficits can result from 
cavernomas through their compressive 
effect without bleeding, having a slowly 
progressive course that can lead to 
diagnostic confusion, without a complete 
imagistic they mimic a clinical setting of 
multiple sclerosis or pontine glioma (34). 
Headache is a usual but nonspecific sign in 
infratentorial cavernomas. It is a very rare 
situation for the brainstem cavernomas to 
produce seizures. The frequency of 
asymptomatic cavernomas is not precisely 
defined but according to Zabramski (52) 
and Brunereau (9, 10) it seems to be even 
more than 40%.  
Natural history 
At the beginning of 1990 (once the MRI 
became widely available) the hemorrhagic 
risk associated with brain cavernoma, was 
more and more accepted. (15). 
The hemorrhagic pattern presents a 
great variability with many terms that 
define the hemorrhagic event in literature 
(1, 2, 6, 15, 16, 23, 38, 41, 43, 44, 54). 
Hemorrhage is the main problem also from 
a clinical and a therapeutic point of view. 
Even if this problem seems facile some 
hypothesis are wrong. The problem starts 
with a definition for hemorrhage and ends 
in particular responses for every patient. On 
one side, the hemorrhage can be defined 
based on clinical status: de novo or sudden 
onset of new symptoms in a cavernoma 
patient, resulted from a rebleeding episode. 
There are many descriptions and many 
terms used in literature to define a 
hemorrhage associated with cavernoma: 
clinical significant cavernoma; symptomatic 
hemorrhage, important hemorrhage, 
microhemorrhage, intralezional diapedesis, 
or perilezional clinical significant 
hemorrhage, subclinical hemorrhage, etc. 
(1, 20, 23, 8). Still the problem of 
hemorrhage in cavernomas is a reason for 
debate regarding the risk of hemorrhage 
and the rate of rebleeding in patients with 
cavernomas. Most of the estimates take into 
account the fact that cavernomas are present 
at birth and they base the appreciation of 
the risk of hemorrhage and risk of 
rebleeding on this supposition.  
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Del Curling et al. (15) and de Robinson 
et al. (43) were the first to calculate the 
annual rate of hemorrhage, between 0,25% 
and 0,7% / year.  
Hemorrhage risk factors 
Hemorrhagic onset (hemorrhagic 
presentation) has a negative impact on the 
natural history of cavernoma. Patients with 
a hemorrhagic onset have a higher risk of 
rebleeding than patients with some other 
symptomatic onset or accidentally 
diagnosed, 22,9 per year, compared to 
0,39% per year (1, 23). Other studies (31, 
35) did not recognize the presence of 
hemorrhage as an independent risk factor, 
but observed that patients with 
hemorrhagic or non-hemorrhagic onset 
associated with focal neurological deficit 
had higher rebleeding rates than those 
without neurological deficits. (8,9% 
compared to 0,4% /patient-year). A 
spontaneous drop off of the rebleeding risk 
after approximately 2 years after a 
hemorrhagic episode was remarked, the so 
called “ temporal clustering” phenomenon 
(5,50). 
Anatomic location. A higher rate of 
symptomatic recurrent hemorrhage was 
reported related to infratentorial location 
than in supratentorial location (39), 
3,8%/patient/year compared to 
0,4%/patient/year, also a higher incidence of 
invalidant neurological deficits in 
infratentorial location compared to 
supratentorial ones (44). Patients with 
supratentorial cavernomas have a low 
probability of fatal hemorrhage, most of the 
patients having a complete or almost 
complete  recovery after the first 
hemorrhagic episode, but this situation is 
not true for infratentorial location where a 
hemorrhage, especially in pons can be fatal. 
In Fritschi’s (17),  series of 139 brainstem 
cavernomas a high rate of symptomatic 
hemorrhage of 2,7% /patient/year and 21% 
/patient/year rebleeding rate  was 
encounted.   
In the series published by Porter (40), 
the symptomatic hemorrhage rate and the 
symptomatic rebleeding rate are even 
higher 5%/patient/year respectively 
30%/patient/year. 
Female sex. Some authors (4, 40, 43) 
reported a significant growth of the 
hemorrhage rate in women, but in most of 
them the gender difference wasn't 
significant. (17, 23, 39). 
De novo development. Initially all 
cavernomas were thought to be congenital. 
There are many proofs of de novo 
cavernoma development. Radiotherapy is 
one of the factors in favor of de novo 
cavernoma formation (36), along with 
genetic factors, viruses, hormonal 
influences during pregnancy, and local 
dissemination at biopsy. De novo 
cavernoma formation was recently 
confirmed based on MRI studies in patients 
with familial form. Even more studies 
counted the de novo cavernoma formation 
incidence between 0,1 and 0,6 new lesions 
/patients/year (21, 25, 52). This  
phenomenon is much more frequent in 
familial than in sporadic form, respectively 
27,5%-30% of the patients with familial 
form have de novo cavernomas while only 
4,1% of patients with sporadic form develop 
de novo cavernomas with time (25, 26,41). 
Size Dynamics. De novo cavernoma 
formation isn't the sole dynamic aspect of 
cavernomas, they can also report important 
growth with time. The best study to prove 
the dynamics of cavernomas is that of 
Clatterbuck (12), who observed 68 patients 
with 114 cavernomas, on MRI on an 
average period of 3,7 years. He concluded 
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that 22% of lesions were stable, 43% 
reported growth and 35% shrinkage. There 
is no study so far to associate the growth of 
cavernomas with the risk of hemorrhage. 
Inherited form. Even if most of the 
cavernomas are considered to be sporadic, 
more and more familial cases were observed 
in the last two decades. These cases have an 
autosomal dominant inheritage, and are 
most common in hispanic population. 
Recent studies showed at least 3 distinct 
genes related to the familial form of disease, 
two of them being precisely located. 
The first gene is CCM1 (cavernous 
cerebral malformation 1) and is located on 
chromosomal 7 at 7q11.2-q21 locus. 
Another known gene is KRIT1, named 
after the corresponding protein Gene 
CCM1 is present in 40% of familial 
cavernomas. The precise function of 
KRIT1 is unknown it is probably a tumor 
suppressor (13, 14, 19, 28, 53). The second 
gene is CCM2. This is located at 7p15-p13 
and it codifies the protein malcaverin. 
About 20% of familial forms may be related 
to a mutation in CCM2. The third gene 
identified is CCM3, located on 
chromosome 3 at 3q. The function of this 
gene and its association with cavernoma is 
still under research. All the 3 genes seem to 
have implications in angiogenesis. As from 
2004 January tests for CCM 1 mutations 
are available and in short time tests for 
CCM 2 will be available. Recent studies 
suggest the presence of another gene (7, 
29). Also genetic etiologies were 
demonstrated in familial forms in 70% of 
cases the genetic influence is yet to be 
established in sporadic forms. Sporadic 
forms can be caused by a loss of function of 
CCM1 in heterozygotes. The familial form 
may influence the risk of hemorrhage; 
given the multiple cavernomas and the high 
de novo formation rate, in spite of the fact 
that no higher hemorrhagic rate has been 
identified per lesion.  
Analyzing the literature data on 
hemorrhage related to brainstem 
cavernoma we can conclude:  
•patients with brainstem cavernoma 
have a significantly higher risk of 
hemorrhage of  5%/year (40), even if some 
authors found smaller rates (24), of only 
2.46%/year;  
•the rate of rebleeding after a 
symptomatic hemorrhage is 30% per year 
(40);  
•the rate of bleeding is not related with 
patients gender (1,35,43);  
•young age (under 35 years) seems to be 
related to a higher rate of bleeding (24);  
•cavernomas with dimensions of at least 
10 mm have a higher risk of bleeding (24) 
•morbidity rate in brainstem 
cavernomas is  8% (24). 
Conclusions 
Decision making in infratentorial 
cavernomas treatment is strictly related to 
the surgical morbidity and the risks in the 
natural history of the disease. Prospective 
data in literature to predict the evolution for 
every individual patients are lacking so far.  
A metaanalysis over a long period of time is 
required to elucidate the natural history of 
brainstem cavernomas and to identify the 
cavernomas with high potential of 
neurologic deficits. A good understanding 
of the natural history provides the surgeon 
the ability to evaluate the relative risk 
associated to every treatment method. For 
infratentorial cavernomas, the analysis of 
the relative risk is very difficult given the 
sparse cases reported in literature and the 
statistical analysis that limits any. In 
addition, any reported case has an 
 
 
 
388          M. Gorgan et al          Natural history of infratentorial cavernous malformations 
 
 
 
individual variability like the clinical and 
neurological status, age, associated disease, 
accessibility according to location. 
Moreover the experience that the 
neurosurgeon has in treating these lesions is 
what matters. 
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